Generic name: rosiglitazone maleate
Dosage form: tablet, film coated
This dosage information does not include all the information needed to use Avandia safely and effectively. See full prescribing information for Avandia.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
â€‹Prior to prescribing AVANDIA, refer to Indications and Usage (1) for appropriate patient selection. Only prescribers enrolled in the AVANDIA-Rosiglitazone Medicines Access Program can prescribe AVANDIA [see Warnings and Precautions (5.3)].
AVANDIA may be administered at a starting dose of 4 mg either as a single daily dose or in 2 divided doses. For patients who respond inadequately following 8 to 12 weeks of treatment, as determined by reduction in fasting plasma glucose (FPG), the dose may be increased to 8 mg daily. Increases in the dose of AVANDIA should be accompanied by careful monitoring for adverse events related to fluid retention [see Boxed Warning and Warnings and Precautions (5.1)]. AVANDIA may be taken with or without food.
The total daily dose of AVANDIA should not exceed 8 mg.
Patients receiving AVANDIA in combination with other hypoglycemic agents may be at risk for hypoglycemia, and a reduction in the dose of the concomitant agent may be necessary.
Specific Patient Populations
Renal Impairment: No dosage adjustment is necessary when AVANDIA is used as monotherapy in patients with renal impairment. Since metformin is contraindicated in such patients, concomitant administration of metformin and AVANDIA is also contraindicated in patients with renal impairment.
Hepatic Impairment: Liver enzymes should be measured prior to initiating treatment with AVANDIA. Therapy with AVANDIA should not be initiated if the patient exhibits clinical evidence of active liver disease or increased serum transaminase levels (ALT >2.5X upper limit of normal at start of therapy). After initiation of AVANDIA, liver enzymes should be monitored periodically per the clinical judgment of the healthcare professional. [See Warnings and Precautions (5.6) and Clinical Pharmacology (12.3).]
Pediatric: Data are insufficient to recommend pediatric use of AVANDIA [see Use in Specific Populations (8.4)].